List view / Grid view
Therapeutic antibodies play a key role in addressing unmet medical needs. Here, Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases, helping to mediate interactions between circulating immune cells and influencing the intensity and…
Listen to this episode to discover how microbiomics is being leveraged to translate gut microbiome findings into new therapeutic options.
The relationship between insulin and ageing in flies could have far-reaching implications for diabetes and obesity drugs for humans.
Proscia has launched two new products which will help to accelerate discovery and development of new therapies and diagnostics.
Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in hematologic cancers. However, its use in solid tumours has been limited by off-target radiation and toxicity, with few clinical trials advancing beyond phase II. Alexander…
Researchers have identified underlying KRAS mutations which drive associated risk of particular clinical outcomes.
Sygnature Discovery has created a platform named SCANME, which can scale up human disease modelling to develop novel therapeutics.
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
Biolojic Design is redefining antibody therapies by creating “programmable” antibodies that intelligently target well-validated autoimmune and oncology pathways. In this Q&A, CEO and founder Yanay Ofran, PhD, describes Biolojic’s groundbreaking approach, which leverages AI and machine learning to design antibodies capable of adjusting their behaviour based on their biological environment.…
Tune into this episode which explores how engineered tRNAs could treat thousands of rare diseases and cancers that share the same mutation.
The researchers discovered that anti-PD-1 autoantibodies influence the outcome of Atezo/Bev therapy for hepatocellular carcinoma.
Following high-throughput drug screening of the tumour organoids, an effective FDA-approved treatment was identified.
Researchers have identified over 3,000 harmful genetic changes that could disrupt normal RAD51C function.
In this Q&A, Kristina Torfgård, CEO of IRLAB Therapeutics, discusses the Company’s current drug development pipeline, including two promising preclinical projects. Kristina also details their proprietary drug discovery and development platform which has enabled the production of many first-in-class candidates, and what she envisions for the future.
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
